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REVIEW
Evolving Role for Pharmacotherapy in NAFLD/NASH
Suzanna L. Attia1, Samir Softic1,2,3 and Marialena Mouzaki4,*
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent, dynamic disease that occurs across the age spectrum and 
can lead to cirrhosis and hepatocellular carcinoma. There are currently no US Food and Drug Administration (FDA) approved 
treatments for NAFLD; however, this is a field of active research. This review summarizes emerging pharmacotherapies for 
the treatment of adult and pediatric NAFLD. Investigated pharmacotherapies predominantly target bile acid signaling, insulin 
resistance, and lipid handling within the liver. Three drugs have gone on to phase III trials for which results are available. Of 
those, obeticholic acid is the single agent that demonstrates promise according to the interim analyses of the REGENERATE 
trial. Obeticholic acid showed reduction of fibrosis in adults with nonalcoholic steatohepatitis (NASH) taking 25 mg daily for 
18 months (n = 931, reduction in fibrosis in 25% vs. 12% placebo, P < 0.01). Ongoing phase III trials include REGENERATE and 
MAESTRO-NASH, which investigates thyroid hormone receptor-β agonist MGL-3196. Outcomes of promising phase II trials 
in adults with NASH are also available and those have investigated agents, including the fibroblast growth factor (FGF)19 
analogue NGM282, the GLP1 agonist liraglutide, the FGF21 analogue Pegbelfermin, the sodium glucose co-transporter 2 
inhibitor Empagliflozin, the ketohexokinase inhibitor PF-06835919, the acetyl-coenzyme A carboxylase inhibitor GS-0976, 
and the chemokine receptor antagonist Cenicriviroc. Completed and ongoing clinical trials emphasize the need for a more 
nuanced understanding of the phenotypes of subgroups within NAFLD that may respond to an individualized approach to 
pharmacotherapy.
Nonalcoholic fatty liver disease (NAFLD) affects up to 1 bil-
lion individuals worldwide1 and is the most common cause 
of elevated liver enzymes in children. End-stage liver dis-
ease and/or hepatocellular carcinoma secondary to NAFLD 
are among the leading causes of liver failure in adults in the 
United States. Effective and affordable treatments to reduce 
the medical and societal burden of this increasingly preva-
lent condition are urgently needed.2,3 NAFLD represents a 
spectrum of diseases ranging from hepatocellular fat depo-
sition (nonalcoholic fatty liver) to steatohepatitis (nonalcoholic 
steatohepatitis (NASH) with or without fibrosis) to cirrhosis. 
NAFLD is a dynamic disease that can progress to cirrhosis, 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THIS 
TOPIC?
✔  NAFLD affects up to one billion individuals globally 
and is the most common cause of elevated liver en-
zymes in children. Mechanisms contributing to hepatic 
steatosis and fibrosis include increased dietary fat in-
take, alterations in lipid generation and transport, and 
the influences of insulin resistance, inflammation, and 
oxidative stress. Despite prior clinical trials targeting 
these mechanisms, consistently effective pharmaco-
therapy remains lacking.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  This study addresses the question of what novel phar-
macotherapies for NAFLD in stage 2 or 3 clinical trials 
exist and investigates their strengths and limitations.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  This study shows that novel pharmacotherapies for 
NAFLD are limited and not yet ready for clinical use. 
The only phase 3 trial to date with encouraging results 
is REGENERATE; this study shows the potential for obet-
icholic acid over placebo to improve hepatic fibrosis but is 
limited by its small effect in only one quarter of subjects.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE?
✔  This study shows that novel pharmacotherapy for 
NAFLD is still an active and highly-needed area of ongoing 
investigation. This study suggests that in the future, pa-
tients with NAFLD will likely require combination therapy 
in order to address the multiple and potentially individual-
ized mechanisms of their hepatic steatosis and fibrosis.
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but in a small percent of patients it may also spontaneously 
regress.4 With the exception of cirrhosis, the histologic find-
ings associated with NAFLD/NASH are generally reversible 
with treatment. The most important treatment is lifestyle 
modification leading to weight loss and enhanced physical 
activity.5 Lifestyle interventions, however, have proven chal-
lenging both to implement and to sustain over time; this 
underscores the need for effective pharmacotherapy.6 The 
objective of this review is to summarize the current medical 
literature on emerging pharmacotherapy for the treatment of 
both adult and pediatric patients with NAFLD.
PATHOPHYSIOLOGY
NAFLD is the result of multiple, often concurrent, hits to 
the liver that originate from dietary overnutrition, impaired 
hormonal signaling (particularly insulin), defects in cellular me-
tabolism that regulate hepatocellular lipid handling, changes 
in the intestinal microbiome in the context of a compromised 
intestinal barrier, and augmented proinflammatory/profibrotic 
processes. The pathogenesis of NAFLD has been extensively 
reviewed elsewhere.7 Briefly, steatosis occurs when there is 
an imbalance between the mechanisms that regulate lipid 
handling within the liver. Sources of hepatic fat include dietary 
intake, fatty acid flux to the liver from adipose tissue, as well 
as hepatic de novo lipogenesis (e.g., conversion of carbohy-
drates into fatty acids by the hepatocyte).8 Insulin resistance 
is an important driver of lipogenesis in the context of NAFLD.9 
Mechanisms to attenuate hepatic steatosis include increased 
mitochondrial fatty acid oxidation, decreased hepatic lipo-
genesis, and enhanced lipid export from the hepatocytes in 
the form of very low-density lipoproteins. When there is an 
imbalance between input/synthesis vs. export/oxidation of 
hepatocellular fat, hepatic steatosis develops. Furthermore, 
the accumulation of toxic lipid species can trigger the devel-
opment of lipotoxicity, oxidative stress, as well as immune cell 
and stellate cell activation, ultimately leading to the develop-
ment of hepatic inflammation and fibrosis.10 Gene expression 
regulated by PNPLA3, and TM6SF2, bile acid signaling, 
AMPK signaling, insulin, and adipokine signaling modulates 
hepatocellular lipid handling.11,12 Recent data suggest that in-
testinal health and particular gut barrier integrity is crucial to 
prevent microbial signals (e.g., endotoxemia and/or bacteri-
ally derived ethanol) from contributing to the pathogenesis of 
NAFLD.13,14 Treatment approaches investigated to date have 
targeted many of these mechanisms (Figure 1).
SUMMARY OF PRIOR TRIALS INVESTIGATING 
MEDICAL OPTIONS FOR THE TREATMENT OF NAFLD
Various treatments have been investigated for the manage-
ment of both adult and pediatric NAFLD.
• Metformin: Metformin has been studied in both adults 
and children with NAFLD. In adults, a wealth of 
data have shown that metformin can improve serum 
aminotransferase elevations and ameliorate insulin 
resistance; however, it does not have a meaningful 
impact on liver histology.15,16 Similarly, in children, 
metformin does not alter histological outcomes.17
• Thiazolidinediones (TZD): Pioglitazone has been stud-
ied in adults with NASH (with and without type 2 dia-
betes mellitus (T2DM)) and is superior to placebo in 
resolving NASH, reducing (necro)inflammation, and 
fibrosis.18 Its use is associated with weight gain, how-
ever, a significant concern for patients with NAFLD, as 
well as osteopenia and increased risk of fractures in 
older adults.
• Vitamin E: The antioxidant vitamin E has been studied 
in both nondiabetic adults and children with NAFLD. 
In adults, vitamin E is superior to placebo in improving 
histologic components of NASH. However, due to the 
lack of data from patients with diabetes, its use is not 
recommended in diabetics with NASH.18 In children, 
vitamin E is also successful at improving histology 
(e.g., NASH resolution) in a proportion of patients.17
• Other treatments: Various other treatments have been 
studied for the treatment of NAFLD/NASH. These in-
clude probiotics/prebiotics/synbiotics and omega-3 
polyunsaturated fatty acids, among others. Probiotics 
and prebiotics have a beneficial impact on serum ami-
notransferase levels and other markers of metabolic 
dysregulation but have not been studied adequately 
in well-designed trials with histologic end points.19 
Omega-3 fatty acids have been extensively studied, 
predominantly in adults, and although they are benefi-
cial from a steatosis reduction stand point, they do not 
impact key histological outcomes such as inflamma-
tion and fibrosis.20
NOVEL THERAPIES
There are multiple novel pharmacotherapies in various 
phases of investigation (Figure 2). The drugs that have 
gone through phase III investigations are summarized in 
Table 1. Herein, we discuss the most notable medications 
studied grouped by mechanism of action.
Bile acid signaling
Obeticholic acid. Obeticholic acid (OCA) is an farnesoid X 
receptor (FXR) agonist that has been extensively investigated 
for the treatment of NAFLD. FXR agonism has been studied 
because FXR is a bile acid receptor that exerts multiple 
beneficial metabolic effects. FXR contributes to glucose 
regulation at both the hepatic (regulating glycogenolysis 
and gluconeogenesis) and the peripheral level (modulating 
insulin sensitivity in the muscle and the adipose tissue). It 
facilitates intrahepatic lipid handling (balancing de novo 
lipogenesis and fatty acid oxidation) and also exerts anti-
inflammatory effects.12 Following the encouraging results 
of the “FLINT” trial, a phase IIb randomized controlled 
trial (RCT), which showed superiority of 25  mg of OCA 
vs. placebo at reducing NAFLD activity score (NAS) by 2 
points without fibrosis worsening at 72 weeks of treatment 
in adults with NASH,21 a phase III trial followed. The latter, 
called “REGENERATE,” is currently underway; the results 
of its interim analysis recently became available.22 In 
REGENERATE, 10 mg of OCA daily were compared against 
25  mg of OCA daily vs. placebo. Of the 1,968 patients 
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Figure 1 Tissue specific pathways targeted by the novel pharmacotherapies. Novel therapeutics under investigation for treatment 
of nonalcoholic fatty liver disease target metabolic pathways in the liver and other tissue. Fructose metabolized in the liver supports 
de novo lipogenesis. PF-06835919 targets ketohexokinase (KHK), the rate-limiting enzyme of fructose metabolism. Conversion of 
acetyl-CoA to malonly-CoA by acetyl-CoA carboxylase (ACC) is the first committed step in lipogenesis. Malonyl-CoA is an inhibitor of 
carnitine palmitoyltransferase 1 alpha, the rate-limiting enzyme of fatty acid metabolism. GS-0976 is an inhibitor of ACC, thus it prevents 
lipogenesis and increases fatty acid oxidation. However, increased acetyl-CoA pool can serve as a substrate for cholesterol synthesis. 
Once fat is made in the liver, it can be oxidized in the mitochondria to generate energy. Elafibranor is a peroxisome proliferator-activated 
receptors alpha/delta (PPARα/δ) agonist that increases fatty acid oxidation. MGL-3196 and VK2809 are thyroid hormone receptor beta 
(THR-β) agonists that increase the transcription of genes to upregulate mitochondrial fatty acid oxidation. Fibroblast growth factor 19 
(FGF19) analogue NGM282 and Pegbelfermin, as well as PEGylated human FGF21, work in the liver and other tissues via fibroblast 
growth factor receptor 4 (FGFR4) to increase glucose utilization and fatty acid oxidation. Whereas FGF21 is made in the liver, FGF19 is 
made in the intestine through FXR activation. Obeticholic acid (OCA) is a semisynthetic bile acid that is a highly potent FXR agonist in 
the liver and the intestine. Activation of FXR in the liver can decrease conversion of cholesterol to bile acids, so a common side effect 
of OCA is increased serum cholesterol. Lipids made in the liver, but not oxidized, can be excreted from the liver to be utilized or stored 
in other organs, such as adipose tissue. Thiazolidinediones (TZDs) are PPAR gamma (PPARγ) agonists that increase the storage of 
fatty acids in adipocytes. As such, they create a sink for excess fat from the liver to be deposited in the adipose tissue; thus, they 
can also cause weight gain. MSDC-0602K is a second generation PPARγ agonist that has fewer systemic side effects. Liraglutide is 
an analogue of the gut-secreted hormone glucagon-like peptide 1 (GLP-1), which increases glucose-stimulated insulin secretion. It 
also decreases gastric emptying leading to decreased appetite and weight loss. Empagliflozin is a sodium-glucose transport protein 
2 (SGLT-2) inhibitor that works on the kidney to prevent glucose reabsorption, leading to calorie loss via glucosuria. Agonists are in 
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enrolled, 931 with stages 2 and 3 fibrosis were included 
in the interim analysis, which was performed at 18 months 
of treatment. The primary outcomes were either fibrosis 
improvement (≥ 1 stage) without NASH worsening or NASH 
resolution without fibrosis worsening. OCA at 25 mg daily 
was superior to placebo at improving fibrosis (outcome 
met in 25% of patients vs. 12% on placebo, P  <  0.01); 
however, OCA did not meet the other primary outcome of 
NASH resolution. The most common side effect was mild 
to moderate pruritus, which affected 51% of those treated 
with 25 mg OCA vs. 19% of those receiving placebo.
In post hoc analyses of the phase IIb FLINT trial, of the 
200 patients with paired biopsies in the beginning and at the 
end of the 72 week intervention, there was a trend toward in-
creased likelihood of weight loss with the use of OCA (44% 
of OCA vs. 32% of placebo-treated patients lost at least 2% 
of their baseline weight, P = 0.08). This was an added benefit 
to OCA’s therapeutic impact, in addition to reduced serum 
aminotransferases and improved liver histology (reduction 
in NAS).23 However, OCA was associated with an increase 
in serum alkaline phosphatase, low-density lipoprotein-C 
(LDL-C), and hemoglobin A1c levels. Combination treatment 
of OCA with a statin (e.g., 25 mg OCA + 10 mg atorvasta-
tin) has subsequently proven efficacious in preventing the 
LDL-C increase seen with OCA monotherapy.24
NGM282. NGM282 is a humanized fibroblast growth 
factor (FGF)19 analogue, which acts on the same 
pathway as intestinal FXR agonists. Specifically, FGF19 
is released following the activation of intestinal FXR, with 
similar downstream effects as those noted following FXR 
activation.12 Following beneficial effects of treatment with 
FGF19 noted using magnetic resonance imaging-proton 
density fat fraction (MRI-PDFF),25 Harrison et al. reported 
the results of a 12-week open label multicenter trial of 
NGM282 for the treatment of NASH.26 Patients receiving 
subcutaneous NGM282 at either 1 or 3  mg with paired 
biopsies 12  weeks apart were included in the analyses 
(n = 43). NGM282 at 3 mg decreased fibrosis by ≥ 1 stage 
without NASH worsening in 42% of patients and improved 
NAS by ≥  2 points without fibrosis worsening in 63% of 
subjects. A 24-week phase IIb trial of NGM282 for the 
treatment of NASH is currently under way (NCT03912532).
Treatments that improve insulin resistance/metabolic 
dysregulation
Peroxisome proliferator-activated receptor agonists. 
Peroxisome proliferator-activated receptor (PPAR) isoforms 
alpha, delta, and gamma are nuclear hormone receptors 
with the potential to ameliorate NAFLD owing to their effects 
on lipid metabolism (e.g., increased mitochondrial fatty 
Figure 2 Summary of novel medications at the various stages of investigation (active or completed).
Phase 2a
•PPAR agonists:  La branor, Saroglitazar
•GLP1 agonists: Cotadutide
•FGF21 agonists: Pegbelfermin
•SGLT2 inhibitors: Empagl lozin 
•Ketohexokinase inhibitors: PF-06835919
•Thyroid hormone receptor beta (THR-β) agonists: MGL-3196 and VK2809
•Acetyl-coenzyme A carboxylase (ACC) inhibitors: GS-0976 
•Caspase inhibitors: Emricasan
•Other: IMM-124E (colostrum product), Silymarin (milk thistle extract), combinations: 
NCT03987074 (semaglutide, rsocostat, cilofexor)
Phase 2b
•FGF19 analogues: NGM282
•PPAR agonists: Ela branor, MSDC-0602K
•GLP1 agonists: Liraglutide
•Combination therapies: NS-0200 (leucine-metformin-sildena l)
•CC Chemokine receptors 2/5 antagonists: Cenicriviroc
•Galectin inhibitors: Balapectin
Phase 3
•FXR agonists: Obeticholic acid
•Caspase inhibitors: Emricasan
•ASK1 inhibitors:  Selonsertib 
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acid oxidation), insulin sensitivity, and inflammation.27 Both 
PPAR alpha and delta receptors facilitate fat metabolism 
(e.g., fatty acid oxidation), whereas PPAR delta also has 
anti-inflammatory effects.27 PPAR gamma helps regulate 
glucose metabolism as well as fat cell differentiation and 
fatty acid storage.27 Ratziu et al. evaluated the combined 
PPAR α/δ agonist elafibranor in a 52  week phase II 
RCT that compared 120  mg vs. 80  mg of elafibranor vs. 
placebo in adults with NASH (n  =  91–93 per arm).28 The 
primary outcome was reversal of NASH (score 0 in at least 
1 of the components of NAS, namely steatosis, lobular 
inflammation, ballooning) without fibrosis worsening. Per 
original protocol definition, there was no difference for any 
dose of elafibranor on primary outcome. However, in a post 
hoc analysis, a modified definition of the primary outcome 
was introduced showing that reversal of NASH occurred 
when ballooning resolved in the context of no or minimal 
lobular inflammation. Per this analysis, the 120 mg dose led 
to improvement in 19% vs. 12% in those receiving placebo 
(P = 0.045). There was no difference in patients receiving 
the 80  mg dose. Adverse outcomes were similar among 
intervention and control arms. Secondary effects included 
lower LDL-C and triglycerides with higher high-density 
lipoprotein in the intervention groups vs. control. Ongoing 
clinical trials include NCT03008070 assessing efficacy and 
safety of pan-PPAR agonist IVA337/lanifibranor at 800 mg 
and 1,200  mg daily vs. placebo for 24  weeks in adult 
patients with moderate to severe NASH without cirrhosis. 
Another ongoing trial is NCT03639623, a phase IIA, single 
center, open-label, single-arm, 24-week study to evaluate 
the safety, tolerability, and efficacy of PPAR alpha/gamma 
agonist Saroglitazar magnesium 4  mg in liver transplant 
recipients with NAFLD (EVIDENCES VIII).
MSDC-0602K is a second-generation TZD, a PPAR 
gamma agonist. Second generation TZDs, like MSDC-
0602K, do not have the typical TZD side effects of edema, 
fractures, and hypoglycemia due to their mode of action. In 
the EMMINENCE study, Harrison et al. investigated MSDC-
0602K in a phase IIb trial in adults with NASH (defined as 
NAS  ≥  4; with a score ≥  1 in each NAS component) and 
fibrosis stages 1–3.29 After 52 weeks of daily oral MSDC-
0620K at 62.5 mg vs. 125 mg vs. 250 mg vs. placebo given 
to n = 99 to 101 participants per arm, they found no differ-
ence in their primary outcome of improved NAS.
Glucagon-like peptide-1 agonists. Glucagon-like 
peptide-1 (GLP1) agonists improve glucose homeostasis 
by enhancing glucose-dependent insulin secretion and 
inhibiting the release of glucagon from the pancreas. They 
also delay gastric emptying and, when used to treat T2DM, 
contribute to weight loss. These effects are ideal for patients 
with NAFLD, as they are typically overweight or obese and 
have insulin resistance and/or diabetes. The GLP1 agonist 
liraglutide was investigated in a 42-week phase II RCT 
(1.8 mg subcutaneous liraglutide daily vs. placebo) for the 
treatment of NASH.30 The primary outcome was definite 
NASH resolution without worsening of fibrosis. The relative 
risk of NASH resolution was 4.3 (P = 0.019) with the use of 
liraglutide, which also led to weight loss and was overall 
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GLP1 and glucagon, was recently shown to be superior to 
liraglutide in reducing weight and serum aminotransferases 
in an adult cohort of patients with diabetes.31 These 
encouraging results are now being investigated further in a 
phase II trial specific to patients with NASH (NCT04019561).
Fibroblast growth factor 21 agonists. FGFs are 
hormones key to cell growth and differentiation.32 FGF21 
is transcriptionally regulated, in part, by PPAR alpha and 
upregulates fatty acid oxidation. FGF21 can also attenuate 
proinflammatory signals. Sanyal et al. investigated the 
FGF21 analogue pegbelfermin (BMS-986036) given via 
subcutaneous injection in a 16-week phase IIa trial.33 The 
trial recruited patients with NASH, stages 1–3 fibrosis, and 
≥  10% hepatic fat fraction by MRI-PDFF and compared 
10  mg daily, vs. 20  mg weekly pegbelfermin vs. placebo 
(24–26 adults in each group).33 Both daily and weekly 
treatments were superior to placebo in achieving the 
primary outcome of PDFF reduction (10 mg daily: −6.8%, 
P = 0.0004 vs. 20 mg weekly: −5.2, P = 0.008 vs. placebo 
−1.30%) with no difference for those with or without 
T2DM. Anti-pegbelfermin and anti-FGF21 antibodies were 
detected in the majority of patients, decreased in most by 
the end of treatment, and did not affect outcome. Notable 
adverse outcomes were diarrhea and nausea.
Sodium glucose co-transporter 2 inhibitors. Sodium 
glucose co-transporter 2 (SGLT2) inhibitors act by inhibiting 
reabsorption of glucose in the kidney and can also inhibit 
de novo lipogenesis in the liver.34 Due to their action, they 
contribute to weight loss and improvements in systolic 
blood pressure.35 SGTL2 inhibitors have been used for 
the treatment of T2DM and more recently have been 
investigated for the treatment of NAFLD, particularly in 
patients with diabetes, in small studies. Empagliflozin (10 mg 
daily ×20 weeks) was compared against standard treatment 
for diabetes in a cohort of adults with diabetes with NAFLD 
with a primary outcome of change in MRI-PDFF.36 Although 
empagliflozin was superior to the standard of care at 
reducing the fat fraction, the reduction was modest (only 5% 
from baseline), and the difference from the control group at 
20 weeks was only 4%. No significant adverse events were 
noted in this study. The effect of SGLT2 inhibitors on liver 
histology remains to be investigated.
Fructose metabolism. Dietary fructose strongly increases 
hepatic de novo lipogenesis37,38 and decreases hepatic 
fatty acid oxidation,39 thus predisposing to development of 
NAFLD. The rate-limiting enzyme of fructose metabolism 
is ketohexokinase (KHK), which is increased in adult 
subjects with biopsy-proven NAFLD40 and in obese 
adolescents with more severe forms of NAFLD.38 In animal 
studies, knockdown of KHK improves NAFLD and insulin 
resistance.38,41 Small molecule inhibitors of KHK have been 
of interest to pharmaceutical industry for a long time, but 
initial KHK inhibitors lacked specificity.42,43 More recently, 
Pfizer developed a potent reversible inhibitor of human 
KHK.44 In a phase II study of 53 subjects with NAFLD 
(> 6% liver fat assessed by MRI-PDFF), subjects received 
either placebo or the KHK inhibitor PF-06835919 at 75 or 
300 mg of once daily dosing for 6 weeks (NCT03256526). 
Participants treated with 300 mg of KHK inhibitor showed 
a 26.5% reduction in PDFF (P  =  0.039) from baseline as 
compared with the placebo group. A dose-dependent 
trend in decrease from baseline was also observed for 
liver enzymes (alanine aminotransferase (ALT), aspartate 
aminotransferase, and gamma glutamyltransferase), in a 
homeostasis model of assessment of insulin resistance, 
and in markers of systemic inflammation (hs-CRP, IL-6, 
and increased adiponectin) in the 300 mg group relative to 
placebo.45 Fructose may also directly and indirectly induce 
hepatic insulin resistance46 leading to hyperinsulinemia; this 
further stimulates hepatic lipogenesis.47 Due to the effect of 
fructose on hyperinsulinemia, the encouraging initial results 
of PF-06835919 are being further investigated in a phase II 
study of 150 participants with MRI-PDFF liver fat of > 8% 
and T2DM treated with placebo or PF-06835919 at 150 mg 
or 300 mg once daily for 16 weeks (NCT03969719).
Thyroid hormone receptor. Thyroid hormone regulates 
glucose and lipid metabolism, food intake, and the oxidation 
of fatty acids.48 Systemic thyroid hormone replacement 
therapy, however, is not indicated for the treatment of 
obesity and NAFLD due to adverse cardiac and bone effects. 
Recently, a more selective thyroid hormone receptor beta 
(THR-β) agonist has been developed to optimize beneficial 
effects on the liver while minimizing the actions on heart 
and bone that are mainly mediated by THR alpha (THR-α). 
Two THR-β agonists, MGL-3196 and VK2809, are currently 
in clinical development.
In a phase II study of 125 adults with biopsy-confirmed 
NASH, MGL-3196 at 80 mg daily dose with ± 20 mg dose 
adjustment resulted in 32.9% relative reduction of hepatic 
fat as assessed by change in MRI-PDFF compared with 
10.4% reduction in placebo-treated patients after 12 weeks 
(NCT02912260). After 36  weeks of treatment, MGL-3196 
resulted in a sustained 37.3% reduction in liver fat com-
pared with 8.5% reduction in the placebo treated group. In 
spite of reduced liver fat at 12 weeks, there was no differ-
ence in serum ALT; but with longer exposure at 36 weeks, 
a significant reduction in ALT was observed. NASH resolu-
tion, defined as ballooning score of 0, inflammation score 
of 0 or 1, with ≥ 2-point reduction in NAS on liver biopsy, 
was a secondary end point in the study. NASH resolution 
was observed in 27% of patients treated with MGL-3196 
compared with 6% in those receiving placebo (P = 0.018) 
at 36  weeks. Similarly, NASH resolution was significantly 
greater (P  =  0.017) in the MGL-3196 group (46%) com-
pared with placebo (19%) in patients who lost <  5% of 
body weight. Interestingly, overall improved outcomes in 
subjects treated with MGL-3196 occurred with no change 
in total body weight, indicating that improved liver me-
tabolism is sufficient to induce NASH resolution. Whereas 
several other classes of medication under development for 
the treatment of NASH result in dyslipidemia, treatment with 
MGL-3196 resulted in reductions in multiple atherogenic 
lipids including LDL-C, triglycerides, apolipoprotein B, and 
CIII. Side effects of MGL-3196 therapy were minimal and 
mainly included transient diarrhea. These promising findings 
are being further explored in MAESTRO-NASH, a phase III 
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clinical trial in patients with NASH and stage F2–F3 fibrosis 
(NCT03900429).
A second THR-β selective agonist VK2809 is being eval-
uated for treatment of NASH in a phase IIa clinical study 
(NCT02927184). In this study, 45 patients with liver fat con-
tent ≥ 8% as assessed by MRI-PDFF, LDL-C ≥ 110 mg/dL, 
and triglycerides ≥ 120 mg/dL were randomized to receive 
either oral VK2809 doses of 5 mg daily, 10 mg every other 
day, 10  mg daily, or placebo for 12  weeks. At the end of 
the study, median relative change from baseline in liver fat 
content was 53.8% for 5 mg daily (P = 0.0001), 56.5% for 
10 mg every other day (P = 0.0018), and 59.7% for 10 mg 
daily (P = 0.0004), vs. 9.4% for placebo.49 Surprisingly, ALT 
levels increased transiently at the onset of treatment, but 
after 12 weeks of administration, they were not different in 
subjects that received VK2809 or placebo.50 This study is 
being followed up by VOYAGE, a phase IIb study of 337 sub-
jects with biopsy proven NASH (NAS  ≥  4) and MRI-PDFF 
liver fat fraction ≥ 8% (NCT04173065). This is a 5-treatment 
arm study of placebo and VK2809 at 1.0, 2.5, 5.0, or 10 mg 
daily administered for 52 weeks.
Other
Acetyl-coenzyme A carboxylase inhibitors. Acetyl-
coenzyme A carboxylase (ACC) inhibitors impede de novo 
lipogenesis. GS-0976 is an ACC1 and ACC2 inhibitor 
investigated by Loomba et al. in a phase II clinical trial.51 
Patients with NASH and stages 1–3 fibrosis or MRI-PDFF 
≥  8% and liver stiffness ≥  2.5  kPa were randomized to 
receive 20 mg GS-0976 (n = 49), 5 mg GS-0976 (n = 51), 
or placebo (n  =  26) orally once daily for 12  weeks. The 
primary end point of this trial was safety. The 20  mg 
dose was superior to placebo at reducing the MRI-PDFF 
(median change in hepatic fat fraction with 20 mg: −29%, 
P = 0.0002; vs. 5 mg: −13%, P = 0.43; vs. placebo: −8%). 
Adverse outcomes were nausea, abdominal pain, diarrhea, 
and headache. Hypertriglyceridemia was seen in both 
intervention groups and was concentrated especially in 
participants with TG ≥ 250 mg/dL at baseline. This resolved 
spontaneously or with treatment by week 12.
Combination therapies. L-leucine alters lipid and energy 
metabolism and insulin sensitivity through activation of 
the AmPK/Srtiun 1 pathway. L-leucine in combination with 
metformin and sildenafil has an additive impact on the 
Srtiun 1pathway through endothelial nitric oxide synthase 
activation. NS-0200 is a combination of leucine-metformin-
sildenafil recently investigated by Chalasani et al. in a small 
phase IIb clinical trial.52 They randomized adults (n = 24–32 
per arm) with NAFLD and MRI-PFF ≥  15% to a 16  week 
course of twice daily placebo, low-dose (1.1 g leucine/0.5 g 
metformin/0.5 mg sildenafil), or high-dose NS-0200 (1.1 g 
leucine/0.5  g metformin/1.0  mg sildenafil). The primary 
outcome of change in PDFF did not differ between 
treatment groups and placebo; however, dose-dependent 
decreases in HgbA1c were noted in the NS-0200 arms 
compared with placebo (placebo adjusted decreases of 
0.21%, P = 0.002, and 0.17%, P = 0.016) for low-dose and 
high-dose, respectively). Adverse effects included blurry 
vision, diarrhea, nausea, and erosive gastritis.
Other ongoing clinical trials of combination therapies in-
clude phase II investigation of semaglutide, firsocostat, and 
cilofexor combination therapy (NCT03987074). Semaglutide 
is a GLP1 agonist, firsocostat is an acetyl-CoA carboxylase 
inhibitor, and cilofexor is a bile acid FXR agonist.
Anti-apoptosis/anti-inflammatory agents
Emricasan. Emricasan is a pan-caspase inhibitor and 
given the involvement of caspases in inflammation, 
apoptosis, and necrosis, emricasan has the potential to 
reduce portal pressure and fibrosis. Garcia-Tsao et al. 
investigated emricasan in a phase III clinical trial of NASH-
related cirrhosis with severe portal hypertension.53 Adults 
with NASH-related compensated and decompensated 
(25% of participants) cirrhosis were randomized to 5, 25, or 
50 mg vs. placebo orally twice daily for 24 weeks (n = 65–67 
per arm). Emricasan failed to achieve the primary outcome 
of change in hepatic venous pressure gradient (HVPG); 
however, there was a modest trend toward improved HVPG 
in the compensated patients with higher baseline HVPG 
receiving any dose of Emricasan. There were no notable 
adverse events.
A more recent phase II clinical trial of emricasan assessed 
the effect of 5  mg or 50  mg twice daily vs. placebo for 
72 weeks in adults (n = 105–107 per arm) with histological-
ly-confirmed NASH and stage F1–F3 fibrosis.54 There was 
no difference in the primary outcome of improvement in fi-
brosis without worsening of NASH at 72 weeks.
IMM-124E. IMM-124E is a product from colostrum that 
concentrates anti-E. coli lipopolysaccharide IgG. IMM-
124E’s proposed mechanism for NAFLD treatment is to 
reduce inflammation by binding bacterial endotoxins, and 
it has shown promise in murine models of colitis.55 Due 
to the potential role of endotoxins in the pathogenesis 
of NAFLD, IMM-124E is the intervention of interest in a 
completed but not yet published phase II RCT by Immuron 
Ltd. (NCT02316717).
Silymarin. Silymarin is an antioxidant extract of milk 
thistle (Silybum marianum) with potential in reducing lipid 
peroxidation and hepatic free radical injury. Navarro et al. 
investigated a proprietary silymarin preparation (Legalon) 
in a small phase II trial (SyNCH study).56 Adults with a 
NAS  ≥  4 without cirrhosis were randomized to 420  mg, 
700  mg, or placebo orally 3  times daily for 48–54  weeks 
(n = 25–27 per arm). Legalon was not superior to placebo 
in reaching the primary outcome of reduction in NAS by 
≥ 2 points. Adverse events occurred in the majority of study 
participants receiving Legalon (420  mg: 65.4%, 700  mg: 
55.6% vs. 48% placebo participants). The most common 
reported adverse events were classified as gastrointestinal 
or cardiac complaints (not further specified) with no serious 
adverse events deemed related to the study drug.
Antifibrotic medications
C-C chemokine receptor 2 and 5 inhibitors. C-C 
chemokine receptors 2 and 5 and their ligands contribute to 
the development of fibrosis in the context of NASH rendering 
inhibition of this pathway as an attractive treatment target. 
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CENTAUR is a large phase IIb trial that investigated the 
effectiveness of cenicriviroc (CVC), a dual C-C chemokine 
receptors 2 and 5 antagonist, for the treatment of NASH 
with fibrosis. In this 2-year study, adults with NASH and 
fibrosis stages 1–3 were enrolled and randomized to 
receive 150 mg of CVC or placebo once daily for 1  year. 
Groups A (CVC) and C (placebo) continued with the same 
treatment during year 2, but group B (placebo) crossed 
over to CVC during year 2. At the end of year 1, twice as 
many patients (20% on CVC vs. 10% on placebo, P = 0.02) 
achieved reduction of ≥ 1 stage of fibrosis without NASH 
worsening.57 At the end of year 2, the response in terms 
of fibrosis reduction was similar between groups A and C. 
However, twice as many patients who had responded to 
CVC during year 1 had a sustained response during year 
2 compared with those receiving placebo (60% on CVC 
vs. 30% on placebo). No significant adverse events were 
noted. In summary, a small number of patients responded 
to the antifibrotic effect of CVC. The long-term impact of 
CVC on fibrosis, a slow evolving process, remains to be 
determined.
Galectin inhibitors. Galectins are a group of cytosolic 
proteins that are upregulated in and contribute to 
inflammation and fibrosis. Galectin-3 is secreted specifically 
by macrophages and contributes to macrophage function 
including in apoptosis, adhesion, and angiogenesis. 
Chalassani et al. performed a phase IIb double-blinded 
RCT of galectin-3 inhibitor belapectin in adults with 
cirrhosis and portal hypertension secondary to NASH.58 
After biweekly infusions of 2 or 8  mg/kg belapectin vs. 
placebo for 52 weeks (n = 54 in each arm), they found no 
significant differences in the primary outcome of reduction 
in HVPG. In subgroup analyses, patients without varices 
receiving 2  mg/kg belapectin experienced a reduction in 
HVPG compared with placebo. Adverse events were similar 
across all arms, including placebo, and there were no 
differences in complications of cirrhosis between groups.
Apoptosis signal-regulating kinase 1 inhibitors. 
Apoptosis signal-regulating kinase 1 (ASK1) inhibition is 
another target of interest in NASH, as ASK1 activation leads 
to hepatocyte apoptosis, hepatic inflammation, and fibrosis. 
Selonsertib (GS-4997) is an ASK1 inhibitor. Simtuzumab, 
an antibody against lysyl oxidase-like molecule 2 blocks 
collagen and elastin cross-linkage contributing to fibrosis. 
In a proof of concept study, Loomba et al. investigated 
24  weeks of selonsertib 6 or 18  mg daily orally with 
and without weekly 125  mg simtuzumab injections vs. 
simtuzumab alone in a phase II randomized open-label 
trial in adults with histologically diagnosed NASH with 
stage 2 or 3 fibrosis without cirrhosis (n = 10–32 per arm).59 
They observed trends to reduction in one or more stages 
of liver fibrosis and reduction in progression to cirrhosis 
at 24  weeks in patients receiving 18  mg selonsertib. 
Simtuzumab had no effect on histology. This had also been 
shown in another study previously which was terminated 
early due to simtuzumab’s lack of efficacy60. Adverse 
effects with selonsertib were mild.
Phase III companion trials STELLAR-3 and STELLAR-4 
investigated 6 or 18 mg daily of oral selonsertib vs. placebo 
for 48 weeks in adults with NASH and bridging fibrosis and 
NASH with compensated cirrhosis, respectively.61 These 
studies had > 300 participants in each intervention arm and 
showed no difference with treatment in NASH resolution or 
progression to cirrhosis. There was a slight increase in ad-
verse effects in the intervention groups.
SUMMARY AND CONCLUSIONS
In summary, NAFLD is an area of intense investigations 
for the identification of the optimal medications that, alone 
or in combination, can prevent disease progression and/
or reverse advanced liver disease. In spite of promising 
data from phase II trials, the only phase III trial that has 
generated encouraging results to date is REGENERATE. 
Although obeticholic acid has so far been proven superior 
to placebo in improving fibrosis, it is only effective in one 
quarter of patients. This suggests that additional effective 
medications are still urgently needed, and that NAFLD may 
have subgroups responding differently to various medica-
tion pathways. For that reason, the results of the currently 
enrolling phase III trials are eagerly awaited. It is likely that 
in the future, patients with NAFLD will require a combination 
of medications with each addressing a different aspect in 
the pathogenesis of their particular NAFLD phenotype.
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